Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Review article: Biomedical intelligence

Vol. 147 No. 1920 (2017)

Diagnosis and assessment of renal fibrosis: the state of the art

DOI
https://doi.org/10.4414/smw.2017.14442
Cite this as:
Swiss Med Wkly. 2017;147:w14442
Published
11.05.2017

Summary

Chronic kidney disease (CKD) is defined as an alteration of kidney function and/or structure lasting for more than 3 months and is a major public health issue. Histologically, the severity of CKD correlates with the magnitude of kidney cortical interstitial fibrosis. Estimation of kidney fibrosis is crucial to assess prognosis and guide therapy in both native and allograft kidneys. Biopsy is currently the gold standard for assessing fibrosis with histological techniques. Although this procedure has become safer over recent years, complications and limitations remain. Given these restrictions, new, noninvasive techniques are necessary for the evaluation and follow-up of CKD patients. Radiological methods such as ultrasound and magnetic resonance imaging are emerging for assessment kidney fibrosis. These two techniques have advantages but also limitations. In addition to radiological assessment of fibrosis, urinary and plasma biomarkers are being developed and tested as predictive tools for histological lesions in the kidney. This article reviews the current evidence for these novel techniques in the evaluation of kidney interstitial fibrosis.

References

  1. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41(1):1–12. https://doi.org/10.1053/ajkd.2003.50007
  2. Guessous I, Ponte B, Marques-Vidal P, Paccaud F, Gaspoz JM, Burnier M, et al. Clinical and biological determinants of kidney outcomes in a population-based cohort study. Kidney Blood Press Res. 2014;39(1):74–85. https://doi.org/10.1159/000355779
  3. Fassett RG, Venuthurupalli SK, Gobe GC, Coombes JS, Cooper MA, Hoy WE. Biomarkers in chronic kidney disease: a review. Kidney Int. 2011;80(8):806–21. https://doi.org/10.1038/ki.2011.198
  4. Schainuck LI, Striker GE, Cutler RE, Benditt EP. Structural-functional correlations in renal disease. II. The correlations. Hum Pathol. 1970;1(4):631–41. https://doi.org/10.1016/S0046-8177(70)80061-2
  5. Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int. 2006;69(2):213–7. https://doi.org/10.1038/sj.ki.5000054
  6. Boor P, Sebeková K, Ostendorf T, Floege J. Treatment targets in renal fibrosis. Nephrol Dial Transplant. 2007;22(12):3391–407. https://doi.org/10.1093/ndt/gfm393
  7. Eddy AA. Overview of the cellular and molecular basis of kidney fibrosis. Kidney Int Suppl (2011). 2014;4(1):2–8. https://doi.org/10.1038/kisup.2014.2
  8. Cosio FG, Grande JP, Larson TS, Gloor JM, Velosa JA, Textor SC, et al. Kidney allograft fibrosis and atrophy early after living donor transplantation. Am J Transplant. 2005;5(5):1130–6. https://doi.org/10.1111/j.1600-6143.2005.00811.x
  9. Park WD, Griffin MD, Cornell LD, Cosio FG, Stegall MD. Fibrosis with inflammation at one year predicts transplant functional decline. J Am Soc Nephrol. 2010;21(11):1987–97. https://doi.org/10.1681/ASN.2010010049
  10. Serón D, Moreso F, Ramón JM, Hueso M, Condom E, Fulladosa X, et al. Protocol renal allograft biopsies and the design of clinical trials aimed to prevent or treat chronic allograft nephropathy. Transplantation. 2000;69(9):1849–55. https://doi.org/10.1097/00007890-200005150-00019
  11. Cosio FG, Grande JP, Wadei H, Larson TS, Griffin MD, Stegall MD. Predicting subsequent decline in kidney allograft function from early surveillance biopsies. Am J Transplant. 2005;5(10):2464–72. https://doi.org/10.1111/j.1600-6143.2005.01050.x
  12. Grimm PC, Nickerson P, Gough J, McKenna R, Jeffery J, Birk P, et al. Quantitation of allograft fibrosis and chronic allograft nephropathy. Pediatr Transplant. 1999;3(4):257–70. https://doi.org/10.1034/j.1399-3046.1999.00044.x
  13. Risdon RA, Sloper JC, De Wardener HE. Relationship between renal function and histological changes found in renal-biopsy specimens from patients with persistent glomerular nephritis. Lancet. 1968;2(7564):363–6. https://doi.org/10.1016/S0140-6736(68)90589-8
  14. Roberts IS, Cook HT, Troyanov S, Alpers CE, Amore A, Barratt J, et al.; Working Group of the International IgA Nephropathy Network and the Renal Pathology Society. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int. 2009;76(5):546–56. https://doi.org/10.1038/ki.2009.168
  15. Adamczak M, Gross ML, Krtil J, Koch A, Tyralla K, Amann K, et al. Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats. J Am Soc Nephrol. 2003;14(11):2833–42. https://doi.org/10.1097/01.ASN.0000095248.91994.D3
  16. Boffa JJ, Tharaux PL, Dussaule JC, Chatziantoniou C. Regression of renal vascular fibrosis by endothelin receptor antagonism. Hypertension. 2001;37(2):490–6. https://doi.org/10.1161/01.HYP.37.2.490
  17. Boffa JJ, Lu Y, Placier S, Stefanski A, Dussaule JC, Chatziantoniou C. Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases. J Am Soc Nephrol. 2003;14(5):1132–44. https://doi.org/10.1097/01.ASN.0000060574.38107.3B
  18. Li Y, Wen X, Spataro BC, Hu K, Dai C, Liu Y. hepatocyte growth factor is a downstream effector that mediates the antifibrotic action of peroxisome proliferator-activated receptor-gamma agonists. J Am Soc Nephrol. 2006;17(1):54–65. https://doi.org/10.1681/ASN.2005030257
  19. Wang S, Wilkes MC, Leof EB, Hirschberg R. Noncanonical TGF-beta pathways, mTORC1 and Abl, in renal interstitial fibrogenesis. Am J Physiol Renal Physiol. 2010;298(1):F142–9. https://doi.org/10.1152/ajprenal.00320.2009
  20. Pontrelli P, Rossini M, Infante B, Stallone G, Schena A, Loverre A, et al. Rapamycin inhibits PAI-1 expression and reduces interstitial fibrosis and glomerulosclerosis in chronic allograft nephropathy. Transplantation. 2008;85(1):125–34. https://doi.org/10.1097/01.tp.0000296831.91303.9a
  21. Hotta O, Furuta T, Chiba S, Tomioka S, Taguma Y. Regression of IgA nephropathy: a repeat biopsy study. Am J Kidney Dis. 2002;39(3):493–502. https://doi.org/10.1053/ajkd.2002.31399
  22. Vilayur E, Harris DC. Emerging therapies for chronic kidney disease: what is their role? Nat Rev Nephrol. 2009;5(7):375–83. https://doi.org/10.1038/nrneph.2009.76
  23. Whittier WL, Korbet SM. Timing of complications in percutaneous renal biopsy. J Am Soc Nephrol. 2004;15(1):142–7. https://doi.org/10.1097/01.ASN.0000102472.37947.14
  24. Parrish AE. Complications of percutaneous renal biopsy: a review of 37 years’ experience. Clin Nephrol. 1992;38(3):135–41.
  25. Moreso F, Lopez M, Vallejos A, Giordani C, Riera L, Fulladosa X, et al. Serial protocol biopsies to quantify the progression of chronic transplant nephropathy in stable renal allografts. Am J Transplant. 2001;1(1):82–8. https://doi.org/10.1034/j.1600-6143.2001.010115.x
  26. Marcussen N, Olsen TS, Benediktsson H, Racusen L, Solez K. Reproducibility of the Banff classification of renal allograft pathology. Inter- and intraobserver variation. Transplantation. 1995;60(10):1083–9. https://doi.org/10.1097/00007890-199511270-00004
  27. Furness PN, Taub N ; Convergence of European Renal Transplant Pathology Assessment Procedures (CERTPAP) Project. International variation in the interpretation of renal transplant biopsies: report of the CERTPAP Project. Kidney Int. 2001;60(5):1998–2012. https://doi.org/10.1046/j.1523-1755.2001.00030.x
  28. Farris AB, Alpers CE. What is the best way to measure renal fibrosis?: A pathologist’s perspective. Kidney Int Suppl (2011). 2014;4(1):9–15. https://doi.org/10.1038/kisup.2014.3
  29. Grimm PC, Nickerson P, Gough J, McKenna R, Stern E, Jeffery J, et al. Computerized image analysis of Sirius Red-stained renal allograft biopsies as a surrogate marker to predict long-term allograft function. J Am Soc Nephrol. 2003;14(6):1662–8. https://doi.org/10.1097/01.ASN.0000066143.02832.5E
  30. Sund S, Grimm P, Reisaeter AV, Hovig T. Computerized image analysis vs semiquantitative scoring in evaluation of kidney allograft fibrosis and prognosis. Nephrol Dial Transplant. 2004;19(11):2838–45. https://doi.org/10.1093/ndt/gfh490
  31. Servais A, Meas-Yedid V, Buchler M, Morelon E, Olivo-Marin JC, Lebranchu Y, et al. Quantification of interstitial fibrosis by image analysis on routine renal biopsy in patients receiving cyclosporine. Transplantation. 2007;84(12):1595–601. https://doi.org/10.1097/01.tp.0000295749.50525.bd
  32. Nicholson ML, Bailey E, Williams S, Harris KP, Furness PN. Computerized histomorphometric assessment of protocol renal transplant biopsy specimens for surrogate markers of chronic rejection. Transplantation. 1999;68(2):236–41. https://doi.org/10.1097/00007890-199907270-00013
  33. Farris AB, Adams CD, Brousaides N, Della Pelle PA, Collins AB, Moradi E, et al. Morphometric and visual evaluation of fibrosis in renal biopsies. J Am Soc Nephrol. 2011;22(1):176–86. https://doi.org/10.1681/ASN.2009091005
  34. Street JM, Souza AC, Alvarez-Prats A, Horino T, Hu X, Yuen PS, et al. Automated quantification of renal fibrosis with Sirius Red and polarization contrast microscopy. Physiol Rep. 2014;2(7):e12088. https://doi.org/10.14814/phy2.12088
  35. Bamber J, Cosgrove D, Dietrich CF, Fromageau J, Bojunga J, Calliada F, et al. EFSUMB guidelines and recommendations on the clinical use of ultrasound elastography. Part 1: Basic principles and technology. Ultraschall Med. 2013;34(2):169–84. https://doi.org/10.1055/s-0033-1335205
  36. Wilder J, Patel K. The clinical utility of FibroScan(®) as a noninvasive diagnostic test for liver disease. Med Devices (Auckl). 2014;7:107–14.
  37. Gennisson JL, Grenier N, Combe C, Tanter M. Supersonic shear wave elastography of in vivo pig kidney: influence of blood pressure, urinary pressure and tissue anisotropy. Ultrasound Med Biol. 2012;38(9):1559–67. https://doi.org/10.1016/j.ultrasmedbio.2012.04.013
  38. Grenier N, Poulain S, Lepreux S, Gennisson JL, Dallaudière B, Lebras Y, et al. Quantitative elastography of renal transplants using supersonic shear imaging: a pilot study. Eur Radiol. 2012;22(10):2138–46. https://doi.org/10.1007/s00330-012-2471-9
  39. Syversveen T, Brabrand K, Midtvedt K, Strøm EH, Hartmann A, Jakobsen JA, et al. Assessment of renal allograft fibrosis by acoustic radiation force impulse quantification--a pilot study. Transpl Int. 2011;24(1):100–5. https://doi.org/10.1111/j.1432-2277.2010.01165.x
  40. Syversveen T, Midtvedt K, Berstad AE, Brabrand K, Strøm EH, Abildgaard A. Tissue elasticity estimated by acoustic radiation force impulse quantification depends on the applied transducer force: an experimental study in kidney transplant patients. Eur Radiol. 2012;22(10):2130–7. https://doi.org/10.1007/s00330-012-2476-4
  41. Wang L, Xia P, Lv K, Han J, Dai Q, Li XM, et al. Assessment of renal tissue elasticity by acoustic radiation force impulse quantification with histopathological correlation: preliminary experience in chronic kidney disease. Eur Radiol. 2014;24(7):1694–9. https://doi.org/10.1007/s00330-014-3162-5
  42. Lee J, Oh YT, Joo DJ, Ma BG, Lee AL, Lee JG, et al. Acoustic Radiation Force Impulse Measurement in Renal Transplantation: A Prospective, Longitudinal Study With Protocol Biopsies. Medicine (Baltimore). 2015;94(39):e1590. https://doi.org/10.1097/MD.0000000000001590
  43. Lukenda V, Mikolasevic I, Racki S, Jelic I, Stimac D, Orlic L. Transient elastography: a new noninvasive diagnostic tool for assessment of chronic allograft nephropathy. Int Urol Nephrol. 2014;46(7):1435–40. https://doi.org/10.1007/s11255-014-0697-y
  44. Nakao T, Ushigome H, Nakamura T, Harada S, Koshino K, Suzuki T, et al. Evaluation of renal allograft fibrosis by transient elastography (Fibro Scan). Transplant Proc. 2015;47(3):640–3. https://doi.org/10.1016/j.transproceed.2014.12.034
  45. Arndt R, Schmidt S, Loddenkemper C, Grünbaum M, Zidek W, van der Giet M, et al. Noninvasive evaluation of renal allograft fibrosis by transient elastography--a pilot study. Transpl Int. 2010;23(9):871–7.
  46. Sommerer C, Scharf M, Seitz C, Millonig G, Seitz HK, Zeier M, et al. Assessment of renal allograft fibrosis by transient elastography. Transpl Int. 2013;26(5):545–51. https://doi.org/10.1111/tri.12073
  47. Orlacchio A, Chegai F, Del Giudice C, Anselmo A, Iaria G, Palmieri G, et al. Kidney transplant: usefulness of real-time elastography (RTE) in the diagnosis of graft interstitial fibrosis. Ultrasound Med Biol. 2014;40(11):2564–72. https://doi.org/10.1016/j.ultrasmedbio.2014.06.002
  48. Ozkan F, Yavuz YC, Inci MF, Altunoluk B, Ozcan N, Yuksel M, et al. Interobserver variability of ultrasound elastography in transplant kidneys: correlations with clinical-Doppler parameters. Ultrasound Med Biol. 2013;39(1):4–9. https://doi.org/10.1016/j.ultrasmedbio.2012.09.013
  49. Gao J, Rubin JM, Xiang DY, He W, Auh YH, Wang J, et al. Doppler parameters in renal transplant dysfunction: correlations with histopathologic changes. J Ultrasound Med. 2011;30(2):169–75. https://doi.org/10.7863/jum.2011.30.2.169
  50. Perea RJ, Ortiz-Perez JT, Sole M, Cibeira MT, de Caralt TM, Prat-Gonzalez S, et al. T1 mapping: characterisation of myocardial interstitial space. Insights Imaging. 2015;6(2):189–202. https://doi.org/10.1007/s13244-014-0366-9
  51. Hueper K, Gutberlet M, Rong S, Hartung D, Mengel M, Lu X, et al. Acute kidney injury: arterial spin labeling to monitor renal perfusion impairment in mice-comparison with histopathologic results and renal function. Radiology. 2014;270(1):117–24. https://doi.org/10.1148/radiol.13130367
  52. Hueper K, Hensen B, Gutberlet M, Chen R, Hartung D, Barrmeyer A, et al. Kidney Transplantation: Multiparametric Functional Magnetic Resonance Imaging for Assessment of Renal Allograft Pathophysiology in Mice. Invest Radiol. 2016;51(1):58–65. https://doi.org/10.1097/RLI.0000000000000205
  53. Lee VS, Kaur M, Bokacheva L, Chen Q, Rusinek H, Thakur R, et al. What causes diminished corticomedullary differentiation in renal insufficiency? J Magn Reson Imaging. 2007;25(4):790–5. https://doi.org/10.1002/jmri.20878
  54. Huang Y, Sadowski EA, Artz NS, Seo S, Djamali A, Grist TM, et al. Measurement and comparison of T1 relaxation times in native and transplanted kidney cortex and medulla. J Magn Reson Imaging. 2011;33(5):1241–7. https://doi.org/10.1002/jmri.22543
  55. Hueper K, Gueler F, Bräsen JH, Gutberlet M, Jang MS, Lehner F, et al. Functional MRI detects perfusion impairment in renal allografts with delayed graft function. Am J Physiol Renal Physiol. 2015;308(12):F1444–51. https://doi.org/10.1152/ajprenal.00064.2015
  56. Niendorf T, Pohlmann A, Arakelyan K, Flemming B, Cantow K, Hentschel J, et al. How bold is blood oxygenation level-dependent (BOLD) magnetic resonance imaging of the kidney? Opportunities, challenges and future directions. Acta Physiol (Oxf). 2015;213(1):19–38. https://doi.org/10.1111/apha.12393
  57. Hueper K, Rong S, Gutberlet M, Hartung D, Mengel M, Lu X, et al. T2 relaxation time and apparent diffusion coefficient for noninvasive assessment of renal pathology after acute kidney injury in mice: comparison with histopathology. Invest Radiol. 2013;48(12):834–42. https://doi.org/10.1097/RLI.0b013e31829d0414
  58. Inoue T, Kozawa E, Okada H, Inukai K, Watanabe S, Kikuta T, et al. Noninvasive evaluation of kidney hypoxia and fibrosis using magnetic resonance imaging. J Am Soc Nephrol. 2011;22(8):1429–34. https://doi.org/10.1681/ASN.2010111143
  59. Togao O, Doi S, Kuro-o M, Masaki T, Yorioka N, Takahashi M. Assessment of renal fibrosis with diffusion-weighted MR imaging: study with murine model of unilateral ureteral obstruction. Radiology. 2010;255(3):772–80. https://doi.org/10.1148/radiol.10091735
  60. Li Q, Li J, Zhang L, Chen Y, Zhang M, Yan F. Diffusion-weighted imaging in assessing renal pathology of chronic kidney disease: A preliminary clinical study. Eur J Radiol. 2014;83(5):756–62. https://doi.org/10.1016/j.ejrad.2014.01.024
  61. Zhao J, Wang ZJ, Liu M, Zhu J, Zhang X, Zhang T, et al. Assessment of renal fibrosis in chronic kidney disease using diffusion-weighted MRI. Clin Radiol. 2014;69(11):1117–22. https://doi.org/10.1016/j.crad.2014.06.011
  62. Le Bihan D, Poupon C, Amadon A, Lethimonnier F. Artifacts and pitfalls in diffusion MRI. J Magn Reson Imaging. 2006;24(3):478–88. https://doi.org/10.1002/jmri.20683
  63. Friedli I, Crowe LA, Viallon M, Porter DA, Martin PY, de Seigneux S, et al. Improvement of renal diffusion-weighted magnetic resonance imaging with readout-segmented echo-planar imaging at 3T. Magn Reson Imaging. 2015;33(6):701–8. https://doi.org/10.1016/j.mri.2015.02.023
  64. Friedli I, Crowe LA, Berchtold L, Moll S, Hadaya K, de Perrot T, et al. New Magnetic Resonance Imaging Index for Renal Fibrosis Assessment: A Comparison between Diffusion-Weighted Imaging and T1 Mapping with Histological Validation. Sci Rep. 2016;6(1):30088. https://doi.org/10.1038/srep30088
  65. Zhang JL, Sigmund EE, Chandarana H, Rusinek H, Chen Q, Vivier PH, et al. Variability of renal apparent diffusion coefficients: limitations of the monoexponential model for diffusion quantification. Radiology. 2010;254(3):783–92. https://doi.org/10.1148/radiol.09090891
  66. Ghoul BE, Squalli T, Servais A, Elie C, Meas-Yedid V, Trivint C, et al. Urinary procollagen III aminoterminal propeptide (PIIINP): a fibrotest for the nephrologist. Clin J Am Soc Nephrol. 2010;5(2):205–10. https://doi.org/10.2215/CJN.06610909
  67. Teppo AM, Törnroth T, Honkanen E, Grönhagen-Riska C. Urinary amino-terminal propeptide of type III procollagen (PIIINP) as a marker of interstitial fibrosis in renal transplant recipients. Transplantation. 2003;75(12):2113–9. https://doi.org/10.1097/01.TP.0000066809.60389.48
  68. Soylemezoglu O, Wild G, Dalley AJ, MacNeil S, Milford-Ward A, Brown CB, et al. Urinary and serum type III collagen: markers of renal fibrosis. Nephrol Dial Transplant. 1997;12(9):1883–9. https://doi.org/10.1093/ndt/12.9.1883
  69. Ix JH, Biggs ML, Mukamal K, Djousse L, Siscovick D, Tracy R, et al. Urine Collagen Fragments and CKD Progression-The Cardiovascular Health Study. J Am Soc Nephrol. 2015;26(10):2494–503. https://doi.org/10.1681/ASN.2014070696
  70. Guerrot D, Dussaule JC, Mael-Ainin M, Xu-Dubois YC, Rondeau E, Chatziantoniou C, et al. Identification of periostin as a critical marker of progression/reversal of hypertensive nephropathy. PLoS One. 2012;7(3):e31974. https://doi.org/10.1371/journal.pone.0031974
  71. Mael-Ainin M, Abed A, Conway SJ, Dussaule JC, Chatziantoniou C. Inhibition of periostin expression protects against the development of renal inflammation and fibrosis. J Am Soc Nephrol. 2014;25(8):1724–36. https://doi.org/10.1681/ASN.2013060664
  72. Sen K, Lindenmeyer MT, Gaspert A, Eichinger F, Neusser MA, Kretzler M, et al. Periostin is induced in glomerular injury and expressed de novo in interstitial renal fibrosis. Am J Pathol. 2011;179(4):1756–67. https://doi.org/10.1016/j.ajpath.2011.06.002
  73. Satirapoj B, Witoon R, Ruangkanchanasetr P, Wantanasiri P, Charoenpitakchai M, Choovichian P. Urine periostin as a biomarker of renal injury in chronic allograft nephropathy. Transplant Proc. 2014;46(1):135–40. https://doi.org/10.1016/j.transproceed.2013.07.069
  74. Basile DP. The transforming growth factor beta system in kidney disease and repair: recent progress and future directions. Curr Opin Nephrol Hypertens. 1999;8(1):21–30. https://doi.org/10.1097/00041552-199901000-00005
  75. Wang S, Chen Q, Simon TC, Strebeck F, Chaudhary L, Morrissey J, et al. Bone morphogenic protein-7 (BMP-7), a novel therapy for diabetic nephropathy. Kidney Int. 2003;63(6):2037–49. https://doi.org/10.1046/j.1523-1755.2003.00035.x
  76. Wang S, de Caestecker M, Kopp J, Mitu G, Lapage J, Hirschberg R. Renal bone morphogenetic protein-7 protects against diabetic nephropathy. J Am Soc Nephrol. 2006;17(9):2504–12. https://doi.org/10.1681/ASN.2006030278
  77. Sato H, Iwano M, Akai Y, Kurioka H, Kubo A, Yamaguchi T, et al. Increased excretion of urinary transforming growth factor beta 1 in patients with diabetic nephropathy. Am J Nephrol. 1998;18(6):490–4. https://doi.org/10.1159/000013415
  78. Honkanen E, Teppo AM, Törnroth T, Groop PH, Grönhagen-Riska C. Urinary transforming growth factor-beta 1 in membranous glomerulonephritis. Nephrol Dial Transplant. 1997;12(12):2562–8. https://doi.org/10.1093/ndt/12.12.2562
  79. Suthanthiran M, Gerber LM, Schwartz JE, Sharma VK, Medeiros M, Marion R, et al. Circulating transforming growth factor-beta1 levels and the risk for kidney disease in African Americans. Kidney Int. 2009;76(1):72–80. https://doi.org/10.1038/ki.2009.66
  80. Wong MG, Perkovic V, Woodward M, Chalmers J, Li Q, Hillis GS, et al. Circulating bone morphogenetic protein-7 and transforming growth factor-β1 are better predictors of renal end points in patients with type 2 diabetes mellitus. Kidney Int. 2013;83(2):278–84. https://doi.org/10.1038/ki.2012.383
  81. Carr MW, Roth SJ, Luther E, Rose SS, Springer TA. Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc Natl Acad Sci USA. 1994;91(9):3652–6. https://doi.org/10.1073/pnas.91.9.3652
  82. Ho J, Rush DN, Gibson IW, Karpinski M, Storsley L, Bestland J, et al. Early urinary CCL2 is associated with the later development of interstitial fibrosis and tubular atrophy in renal allografts. Transplantation. 2010;90(4):394–400. https://doi.org/10.1097/TP.0b013e3181e6424d
  83. Ho J, Wiebe C, Gibson IW, Hombach-Klonisch S, Gao A, Rigatto C, et al. Elevated urinary CCL2: Cr at 6 months is associated with renal allograft interstitial fibrosis and inflammation at 24 months. Transplantation. 2014;98(1):39–46. https://doi.org/10.1097/01.TP.0000442776.40295.73
  84. Hirt-Minkowski P, Rush DN, Gao A, Hopfer H, Wiebe C, Nickerson PW, et al. Six-Month Urinary CCL2 and CXCL10 Levels Predict Long-term Renal Allograft Outcome. Transplantation. 2016;100(9):1988–96. https://doi.org/10.1097/TP.0000000000001304
  85. Tan RJ, Liu Y. Matrix metalloproteinases in kidney homeostasis and diseases. Am J Physiol Renal Physiol. 2012;302(11):F1351–61. https://doi.org/10.1152/ajprenal.00037.2012
  86. Rödder S, Scherer A, Raulf F, Berthier CC, Hertig A, Couzi L, et al. Renal allografts with IF/TA display distinct expression profiles of metzincins and related genes. Am J Transplant. 2009;9(3):517–26. https://doi.org/10.1111/j.1600-6143.2008.02512.x
  87. Racca MA, Novoa PA, Rodríguez I, Della Vedova AB, Pellizas CG, Demarchi M, et al. Renal dysfunction and intragraft proMMP9 activity in renal transplant recipients with interstitial fibrosis and tubular atrophy. Transpl Int. 2015;28(1):71–8. https://doi.org/10.1111/tri.12445
  88. Yan Q, Sui W, Wang B, Zou H, Zou G, Luo H. Expression of MMP-2 and TIMP-1 in renal tissue of patients with chronic active antibody-mediated renal graft rejection. Diagn Pathol. 2012;7(1):141. https://doi.org/10.1186/1746-1596-7-141
  89. Hirt-Minkowski P, Marti HP, Hönger G, Grandgirard D, Leib SL, Amico P, et al. Correlation of serum and urinary matrix metalloproteases/tissue inhibitors of metalloproteases with subclinical allograft fibrosis in renal transplantation. Transpl Immunol. 2014;30(1):1–6. https://doi.org/10.1016/j.trim.2013.11.004
  90. Zhou D, Tian Y, Sun L, Zhou L, Xiao L, Tan RJ, et al. Matrix Metalloproteinase-7 Is a Urinary Biomarker and Pathogenic Mediator of Kidney Fibrosis. J Am Soc Nephrol. 2017;28(2):598–611.
  91. Niewczas MA, Gohda T, Skupien J, Smiles AM, Walker WH, Rosetti F, et al. Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes. J Am Soc Nephrol. 2012;23(3):507–15. https://doi.org/10.1681/ASN.2011060627
  92. Gohda T, Niewczas MA, Ficociello LH, Walker WH, Skupien J, Rosetti F, et al. Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes. J Am Soc Nephrol. 2012;23(3):516–24. https://doi.org/10.1681/ASN.2011060628
  93. Tonelli M, Sacks F, Pfeffer M, Jhangri GS, Curhan G ; Cholesterol and Recurrent Events (CARE) Trial Investigators. Biomarkers of inflammation and progression of chronic kidney disease. Kidney Int. 2005;68(1):237–45. https://doi.org/10.1111/j.1523-1755.2005.00398.x
  94. Carlsson AC, Larsson TE, Helmersson-Karlqvist J, Larsson A, Lind L, Ärnlöv J. Soluble TNF receptors and kidney dysfunction in the elderly. J Am Soc Nephrol. 2014;25(6):1313–20. https://doi.org/10.1681/ASN.2013080860
  95. Doorenbos CR, van den Born J, Navis G, de Borst MH. Possible renoprotection by vitamin D in chronic renal disease: beyond mineral metabolism. Nat Rev Nephrol. 2009;5(12):691–700. https://doi.org/10.1038/nrneph.2009.185
  96. Mirković K, Doorenbos CR, Dam WA, Lambers Heerspink HJ, Slagman MC, Nauta FL, et al. Urinary vitamin D binding protein: a potential novel marker of renal interstitial inflammation and fibrosis. PLoS One. 2013;8(2):e55887. https://doi.org/10.1371/journal.pone.0055887
  97. Amer H, Lieske JC, Rule AD, Kremers WK, Larson TS, Franco Palacios CR, et al. Urine high and low molecular weight proteins one-year post-kidney transplant: relationship to histology and graft survival. Am J Transplant. 2013;13(3):676–84. https://doi.org/10.1111/ajt.12044
  98. Pallet N, Chauvet S, Chassé JF, Vincent M, Avillach P, Levi C, et al. Urinary retinol binding protein is a marker of the extent of interstitial kidney fibrosis. PLoS One. 2014;9(1):e84708. https://doi.org/10.1371/journal.pone.0084708
  99. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215–33. https://doi.org/10.1016/j.cell.2009.01.002
  100. Bhatt K, Kato M, Natarajan R. Mini-review: emerging roles of microRNAs in the pathophysiology of renal diseases. Am J Physiol Renal Physiol. 2016;310(2):F109–18.
  101. Schena FP, Serino G, Sallustio F. MicroRNAs in kidney diseases: new promising biomarkers for diagnosis and monitoring. Nephrol Dial Transplant. 2014;29(4):755–63. https://doi.org/10.1093/ndt/gft223
  102. Putta S, Lanting L, Sun G, Lawson G, Kato M, Natarajan R. Inhibiting microRNA-192 ameliorates renal fibrosis in diabetic nephropathy. J Am Soc Nephrol. 2012;23(3):458–69. https://doi.org/10.1681/ASN.2011050485
  103. Krupa A, Jenkins R, Luo DD, Lewis A, Phillips A, Fraser D. Loss of MicroRNA-192 promotes fibrogenesis in diabetic nephropathy. J Am Soc Nephrol. 2010;21(3):438–47. https://doi.org/10.1681/ASN.2009050530
  104. Scian MJ, Maluf DG, David KG, Archer KJ, Suh JL, Wolen AR, et al. MicroRNA profiles in allograft tissues and paired urines associate with chronic allograft dysfunction with IF/TA. Am J Transplant. 2011;11(10):2110–22. https://doi.org/10.1111/j.1600-6143.2011.03666.x
  105. Muthukumar T, Lee JR, Dadhania DM, Ding R, Sharma VK, Schwartz JE, et al. Allograft rejection and tubulointerstitial fibrosis in human kidney allografts: interrogation by urinary cell mRNA profiling. Transplant Rev (Orlando). 2014;28(3):145–54. https://doi.org/10.1016/j.trre.2014.05.003
  106. Maluf DG, Dumur CI, Suh JL, Scian MJ, King AL, Cathro H, et al. The urine microRNA profile may help monitor post-transplant renal graft function. Kidney Int. 2014;85(2):439–49. https://doi.org/10.1038/ki.2013.338
  107. Anglicheau D, Muthukumar T, Hummel A, Ding R, Sharma VK, Dadhania D, et al. Discovery and validation of a molecular signature for the noninvasive diagnosis of human renal allograft fibrosis. Transplantation. 2012;93(11):1136–46. https://doi.org/10.1097/TP.0b013e31824ef181
  108. Lv LL, Cao YH, Ni HF, Xu M, Liu D, Liu H, et al. MicroRNA-29c in urinary exosome/microvesicle as a biomarker of renal fibrosis. Am J Physiol Renal Physiol. 2013;305(8):F1220–7. https://doi.org/10.1152/ajprenal.00148.2013
  109. Glowacki F, Savary G, Gnemmi V, Buob D, Van der Hauwaert C, Lo-Guidice JM, et al. Increased circulating miR-21 levels are associated with kidney fibrosis. PLoS One. 2013;8(2):e58014. https://doi.org/10.1371/journal.pone.0058014
  110. Neal CS, Michael MZ, Pimlott LK, Yong TY, Li JY, Gleadle JM. Circulating microRNA expression is reduced in chronic kidney disease. Nephrol Dial Transplant. 2011;26(11):3794–802. https://doi.org/10.1093/ndt/gfr485

Most read articles by the same author(s)